Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Research & Development (2019 - 2025)

Historic Research & Development for aTYR PHARMA (ATYR) over the last 6 years, with Q3 2025 value amounting to $22.1 million.

  • aTYR PHARMA's Research & Development rose 4945.63% to $22.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.6 million, marking a year-over-year increase of 1212.59%. This contributed to the annual value of $54.4 million for FY2024, which is 2856.03% up from last year.
  • aTYR PHARMA's Research & Development amounted to $22.1 million in Q3 2025, which was up 4945.63% from $15.4 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Research & Development peaked at $22.1 million during Q3 2025, and registered a low of $8.9 million during Q1 2022.
  • Moreover, its 4-year median value for Research & Development was $12.5 million (2023), whereas its average is $12.8 million.
  • As far as peak fluctuations go, aTYR PHARMA's Research & Development plummeted by 1445.34% in 2023, and later soared by 4945.63% in 2025.
  • aTYR PHARMA's Research & Development (Quarter) stood at $14.9 million in 2022, then dropped by 14.45% to $12.8 million in 2023, then decreased by 4.13% to $12.2 million in 2024, then surged by 80.98% to $22.1 million in 2025.
  • Its Research & Development stands at $22.1 million for Q3 2025, versus $15.4 million for Q2 2025 and $11.8 million for Q1 2025.